Last checked at 
LONDON (Alliance News) - Drug reformulator N4 Pharma PLC said Monday work to develop a manufacturing process for Nuvec has begun "well" with the team making progress.
Nuvec is a therapeutic nanoparticle platform designed to deliver DNA/RNA into cells to generate proteins in situ.
"The company's strategy for the development of Nuvec technology will be determined by the level of immune response directed towards a protein antigen generated from the DNA/RNA loaded onto the nanoparticles," the company said.
The company said that its collaboration with MedImmune UK has begun "well" and the Nuvec team is making "significant progress developing manufacturing methods for Nuvec particles loaded with therapeutic DNA/RNA encoding protein antigens".
The project with MedImmune, which is owned by AstraZeneca PLC, started in February.
The company added that it will also carry out additional research to identify in which human cells Nuvec nanoparticles are most effective for transfection, as well as characterising dose and duration of response at the site of injection.
N4 Pharma expects to receive the results of the tests in the fourth quarter of 2018.
N4 Pharma shares were down 2.4% at 26.1 pence each on Monday.